CTRI/2023/03/050757尚未招募Unknown
Validation study of Frontier X Plus (FX+) device, Recording Electrocardiogram (ECG) for Rhythm Analysis in patients with and without Atrial Fibrillation (AF)
Fourth Frontier Technologies Pvt. Ltd., (FFTPL)0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age: Adults ( > 18 years of age), both genders
- •2. Subjects presenting in the Outpatient department(OPD) with a known case of AF and/or
- •patients admitted as Inpatients for AF by their treating cardiologist with an indication
- •for a 12-Lead ECG or 24-hour ECG Holter monitoring.
- •3. Subjects presenting in the Outpatient department (OPD) with no known AF and/or
- •patients with suspicious arrhythmic episodes were admitted as Out-/In-patients by their
- •treating cardiologist with an indication for a 12-Lead ECG or 24-hour ECG Holter
- •monitoring.
排除标准
- •1. Subjects with a critical underlying cardiac problem.
- •2. Subjects on a ventilator or any other kind of life support system.
- •3. Subjects assessed to be in a serious or life-threatening situation due to any cause.
- •4. Subject with a chest deformity or skin
研究者
相似试验
尚未招募
不适用
Validation Study of Frontier X Plus (FX+) DeviceAtrial FibrillationNCT06471764Fourth Frontier Technologies Pvt Ltd.125
已完成
不适用
CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid NodulesThyroid Nodule (Benign)NCT06117085Pulse Biosciences, Inc.30
已完成
2 期
Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris PatientsAcne VulgarisNCT01362010Vyne Therapeutics Inc.150
招募中
不适用
CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial FibrillationSurgeryAtrial FibrillationAtrial FibrillationNCT06355063Pulse Biosciences, Inc.30
进行中（未招募）
不适用
Essai de phase II évaluant l'association de FOLFOX et CETUXIMAB avec radiothérapie concomitante en traitement des cancers de l'oesophage de stade III - ERAFOXCarcinome epidermoïde ou glandulaire de l'oesophage de satde III histologiquement prouvé. Tumeurs du cardia à développement oesophagien acceptéesMedDRA version: 8.1Level: PTClassification code 10030151Term: cancer oesophageEUCTR2006-005550-72-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)